

1 The mystery of COVID-19 reinfections: A global systematic 2 review and meta-analysis of 577 cases

3 Rubaid Azhar Dhillon^{1¶}, Mohammad Aadil Qamar^{2¶}, Omar Irfan^{3*}, Jaleed Ahmed Gilani⁴, Usama
4 Waqar⁵, Mir Ibrahim Sajid⁵, Syed Faisal Mahmood⁶

5 ¹Medical College, Riphah International University, Rawalpindi, Pakistan.

6 ²Ziauddin Medical College, Karachi, Pakistan.

7 ³Centre for Global Child Health, Hospital for Sick Children, Toronto, Canada.

8 ⁴Aga Khan University Hospital, Karachi, Pakistan.

9 ⁵Medical College, Aga Khan University, Karachi, Pakistan.

10 ⁶Section of Infectious Diseases, Aga Khan University, Karachi, Pakistan.

11 [¶]These authors contributed equally to this work. RAD and MAQ are Joint first authors.

12

13 **Abstract**

14 **Background**

15 As the COVID-19 pandemic rages on, reports on disparities in vaccine roll out alongside
16 reinfection and reactivation from previously recovered cases have been emerging. With newer
17 waves and variants of COVID-19, we conducted a systematic review to assess the determinants
18 and disease spectrum of COVID-19 reinfection.

19 **Methods**

20 A comprehensive search covering relevant databases was conducted for observational studies
21 reporting Polymerase Chain Reaction (PCR) confirmed infection and reinfection cases. Quality
22 assessment tool developed by the National Institute of Health (NIH) for assessment of case
23 series was used. Meta-analyses were performed using RevMan 5.3 for pooled proportions of
24 findings in first infection and reinfection with 95% confidence interval (CI).

25 **Results**

26 Eighty-one studies reporting 577 cases were included from 22 countries. The mean age of
27 patients was 46.2 ± 18.9 years with males accounting for 45.8% of the study population while
28 179 (31.0%) cases of comorbidities were reported. The average time duration between first
29 infection and reinfection was 63.6 ± 48.9 days. During first infection and reinfection, fever was
30 the most common symptom (41.4% and 36.4%, respectively) whilst anti-viral therapy was the
31 most common treatment regimen administered (44.5% and 43.0%, respectively). Overall,
32 comparable odds of symptomatic presentation and management were reported in the two
33 infections. However, a higher Intensive Care Unit (ICU) admission rate was observed in
34 reinfection compared to first infection (10 vs 3). Ten deaths were reported with 565 patients
35 fully recovering. Respiratory failure was the most common cause of death (7/10 deaths).
36 Seventy-two studies were determined to be of good quality whilst nine studies were of fair
37 quality.

38 **Conclusion**

39 As the first global-scale systematic review of its kind, our findings support immunization
40 practices given increased ICU admissions and mortality in reinfections. Our cohort serves as a
41 guide for clinicians and authorities for devising an optimal strategy for controlling the
42 pandemic.

43 **Keywords:** COVID-19, Reinfection, LMIC, HIC, Reactivation

44

45

46

47

48

49

50

51

52

53

54 **Introduction**

55 The coronavirus, through its rapid spread and emerging variants, started in Wuhan amid
56 December 2019. It was declared a global pandemic in March 2020 and persists as a public
57 healthcare emergency. Over this period of more than a year, till date, the virus has infected
58 more than 165 million individuals globally, and has resulted in more than 3.4 million deaths [1].

59 Currently, there are seven types of corona viruses known to infect humans: 4 are seasonal and
60 cause limited upper respiratory tract infections, but 3 of them, namely SARS coronavirus (SARS-
61 CoV-1), Middle East respiratory syndrome (MERS), and SARS-CoV-2 cause severe disease [2].

62 SARS COV-2, the cause of the current pandemic, causes infection by binding to the angiotensin
63 converting enzyme 2 receptor using a receptor binding domain in its spike protein for cell entry
64 and ultimately, resulting in a respiratory syndrome [2-4]. The currently available vaccines target
65 the spike protein[2]. However, mutations in the spike protein have been implicated in the
66 reduction of small, but significant, efficacy of vaccines [5, 6] highlighting the scale of the
67 challenge COVID-19 places to the world.

68 Even though the world is heralding the development of new vaccines as a potential way
69 forward for a healthy, more “COVID-free” time, the concern of reinfection, recurrence, and
70 mutant variants looms. The Center for Disease Control and Prevention (CDC), in their 27th
71 October 2020 update[7] raised concerns over reactivation of the disease and requested the
72 public to maintain infection control measures, such as wearing a mask in public, maintaining a
73 six feet distance, regular hand washing, and avoiding crowded spaces.

74 Since Tillett et al.,[8] described the first confirmed case of COVID-19 reinfection from the USA,
75 many authors have described their patient experiences of viral recurrence. The reason for this
76 recurrence and its potential public health implication is a question that warrants explanation.
77 Iwasaki et al.,[9] reason that perhaps a scant antibody response following the first infection
78 could be the cause of a relapse. They emphasize on ascertaining a degree of specificity of the
79 antibody (anti-nucleocapsid vs anti-spike antibody) at the time of reinfection, as well as
80 determine the immune correlations of protection.

81 The public concern of whether vaccines could be a potential cure for the viral outbreak remains
82 to be explained, with the obvious apprehension of whether a separate vaccine would be
83 required for every variant of the virus. Till date, they have been four variants with significant
84 mutations in the spike protein that have gained wide spread surveillance: B.1.1.7 (VOC
85 202012/01 or 20B/501Y.V1) which originated in the UK, B.1.351 (20H/501Y.V2) which
86 originated from the Republic of South Africa, and P.1 (B.1.1.28.1) which was reported in
87 travelers coming from Brazil [10]. A fourth double mutant variant of concern, labeled B.1.617
88 coming out from India, has been reported in March 2021 and is being investigated, considered
89 to be a cause of the massive rise in infections in India currently experiencing its second wave
90 [11].

91 A few questions remain though. Firstly, would immunity conferred by the first infection protect
92 individuals from a serious disease process in the reinfection phase? And secondly, does
93 reinfection imply that individuals who are already vaccinated experience a more severe COVID-
94 19 infection? The objective of this review, in addition to providing a comprehensive evidence

95 on COVID-19 reinfections including both pediatric and adult cases, is a unique comparison of
96 first infection and the reinfection disease spectrum, management, and outcomes.

97 **Methods**

98 The protocol of the review is registered with PROSPERO CRD42021239816. The review is
99 reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-
100 Analyses (PRISMA).

101 **Search methods**

102 An exhaustive literature review was conducted on major databases: PubMed, WHO COVID-19
103 Database, Embase, China National Knowledge Infrastructure (CNKI) Database, Google Scholar,
104 manual searches of leading medical journals, and a pre-print server, medRxiv, covering the
105 timeline of January 1st, 2020, to March 16th, 2021. The following keywords were used to
106 conduct the search: COVID-19 and derivatives, reinfection, relapse, reactivation, as shown in S1
107 Table. Complementary searches were conducted in the John Hopkins Health Resource, Chinese
108 and US CDC Library. No language restrictions were applied. Key reference lists were additionally
109 screened for more studies.

110 **Selection strategy**

111 Observational studies (cohorts, case series, and case reports) reporting laboratory-confirmed
112 COVID-19 (RT-PCR) first infection and reinfection were considered for inclusion. Review articles,
113 commentaries, and letters not presenting any original data were excluded. Covidence software

114 (2016 edition) was used for screening by two reviewers independently and in duplicate. Any
115 discrepancies in selection were resolved by a third independent author.

116 **Data extraction and analysis**

117 The shortlisted articles were then extracted independently and in duplicate, on a structured
118 data form by two reviewers. The information extracted was as follows: Author names, date of
119 publication, country, setting of study, type of study, number of patients and age group, patient
120 information (age, gender and comorbidities), clinical evaluation (presenting symptoms in both
121 infections, travel/exposure history and infected family members), diagnostic tests
122 (nasopharyngeal swabs, antibody tests and timelines for initial infection and reinfection),
123 radiographic findings, therapeutic regimen (medications, isolation, and plasma therapy),
124 outcomes for both infections (hospitalization, ICU admission, complications, discharge, and
125 death) and antibody status after both infections. Disaggregated data by age groups (children
126 and adults) was extracted where available.

127 Categorical data was summarized as counts and proportions. The pooled proportions of
128 reported findings were calculated using Review Manager 5.3's random-effects model. I^2 was
129 calculated to examine statistical heterogeneity. The clinical features and outcomes were
130 compared accordingly between first infection and reinfection using pooled proportions and
131 their 95% CIs, supplemented by an odds ratio (OR).

132 **Quality assessment**

133 Quality assessment of included studies was conducted using the tool developed by the National
134 Institute of Health (NIH) for assessment of case series. Two authors independently scored the

135 quality of case series out of 8, based on the clarity of study objectives, case definition,
136 consecutive subject recruitment, comparability of subjects, definition and measurement of
137 outcomes, length of follow-up, statistical methods, and results. A case series scoring 6-8 was
138 considered good quality, 4-5 was considered fair quality and <4 was considered poor quality.
139 Consecutive subject recruitment, comparability of subjects and statistical methods were
140 excluded from the scoring criteria for case reports, which were scored out of 5. Case reports
141 scoring 5 were considered good quality, scoring 3-4 were considered fair quality, and scoring <3
142 were considered poor quality.

143 **Results**

144 The comprehensive literature search yielded a total of 980 studies after removal of duplicates.
145 After title and abstract screening, 87 studies were found to be eligible for a full-text
146 assessment, of which, 81 were found to be eligible according to our inclusion criteria[8, 12-91].
147 The characteristics of the 81 included studies is shown in S2 Table. Six studies were excluded as
148 they presented overlapping or missing data. An overview of the detailed systematic study
149 selection process is presented in the PRISMA flow diagram (Fig 1).

150 **Fig 1. PRISMA Flow diagram of study selection process.**

151 Through consultation with a professional librarian, a search was conducted in leading medical
152 journals and through duplication and screening processes, studies were selected.

153 In terms of study types, 45 studies (55.6%) were case reports, and 36 studies (44.4%) were case
154 series. Studies were reported from 22 countries. Forty-eight out of 81 studies were reported
155 from low-and-middle-income countries (LMICs). More than one-third of the studies were

156 reported from China (28/81, 34.6%), almost one-sixth were from the USA (11/81, 13.6%),
157 accounting together for about half of the studies (39/81, 48.1%) included in our review. The
158 global distribution of studies is shown in Table 1 and S1 Fig.

159 **Table 1. Distribution of studies (N=81) and reinfection cases (N=577) according to country of**
160 **origin included in the review.**

Country	Number of studies	Number of reinfection cases
Belgium	2	2
Brazil	7	45
China	28	423
Colombia	1	1
Ecuador	1	1
France	5	19
Hong Kong	3	3
India	4	8
Iraq	1	26
Israel	1	1
Italy	4	4
Iran	1	9
Netherlands	1	1
Pakistan	1	1
Peru	1	1
Portugal	1	1
Qatar	1	1
UK	3	8
USA	11	14
Turkey	2	3
Switzerland	1	1
Korea	1	4
Total	81	577

161

162 **Demographics and Epidemiology**

163 A total of 577 cases with a mean age of 46.2±18.9 years (range 3.0 – 91.0 years) were included
164 in the study. The gender of study cases was noted to be 45.8% males and 53.7% females. Of the

165 577 cases, approximately one-third of the cases (n=179, 31.0%) were reported to have at least
166 one comorbidity. Reports of having a positive contact history with a close contact or a family
167 member with COVID-19 were found in 87 (15.1%) cases (S2 Table and Table 2). Across 76
168 studies, the average reported time duration between first infection and reinfection was 63.6 ±
169 48.9 days (range 11.0 – 210.0 days).

170 **Table 2. Demographics of Patients.**

Variable	Mean Proportion (%)
Age (Years)	46.2 ± 18.9 years (range 3.0 – 91.0 years)
Gender	
Male	264 (45.8)
Female	310 (53.7)
Not specified	3(0.5)
Contact History Positive	87 (15.1)
Underlying Comorbidities	179 (31.0)
Average time duration between first infection and reinfection	63.6 ± 48.9 days (range 11.0 – 210.0 days)

171

172 **Clinical features during first infection and reinfection**

173 Around three-fourth of our cases were categorized as being mildly symptomatic with only 10
174 cases being classified as severe to critical by their respective studies for disease severity in the
175 first infection. The total number of asymptomatic cases during the first infection was 53 (9.2%)
176 with an increase to 184 (31.9%) cases noted during reinfection (S2 Table). Tian M et al.,[72]
177 reported the highest number of asymptomatic cases (20/577, 3.5%) during the first infection
178 whereas An J et al.,[17] with 27 cases (4.7%) reported the highest number of asymptomatic
179 cases during reinfection. The presence of antibodies was also reported for the total 577 cases,

180 wherein 323 (56.0%) and 364 (63.0%) cases were detected to be positive during first infection
181 and reinfection, respectively.

182 The most common presenting symptoms amongst patients in the first infection were fever
183 (n=239, 41.4%) and cough (n=201, 34.8%), which then accounted for 36.4% (n=210) and 34.8%
184 (n=201) of cases, respectively, during reinfection. Myalgia was reported in 80 (13.9%) cases
185 during first infection which increased to 88 (15.3%) cases during reinfection. The frequencies
186 and odds ratio of other reported signs and symptoms are listed in Fig 2.

187 **Fig 2. Clinical features of First Infection and Reinfection (N=577)**

188 Regarding the radiological imaging during first infection of the 577 cases, almost one-quarter
189 (146/577, 25.3%) had not reported, or did not have, any kind of chest imaging done. Out of
190 those who reported, only 25 (4.3%) cases had a normal finding whereas 295 (51.1%) cases
191 reported an abnormality with Chen et al., [27] reporting the highest occurrence of radiological
192 abnormalities (70 out of 81 cases, 86.4%).

193 **Management of first infection and reinfection**

194 The most administered treatment, as reported by the study results, was antiviral therapy
195 accounting for 44.5% (n=257) and 43.0% (n=248) of cases during first infection and reinfection,
196 respectively. Administration of antibiotics was lower at 14.4% (n=83) and 13.2% (n=76) for first
197 infection and reinfection respectively (Fig 3).

198 **Fig 3. Management of First Infection and Reinfection (N=577)**

199 In the study by He et al. [42], 60% of patients were administered steroids during both
200 infections, which was reported to be the highest use of steroids amongst studies reported to
201 date. However, in our data, the overall use of steroids stood at 16.6% (n=96) and 12.1% (n=70)
202 during the respective infections. Traditional Chinese medicine and interferon administration
203 were reported at 13.9% (n=80) and 10.7% (n=62) during the first infection and 26.7% (n=154)
204 and 7.6% (n=44) during reinfections, respectively.

205 Lastly, our results show that the use of low flow oxygen stood at 6.1% (n=35) of cases during
206 the first infection which then doubled to 12.3% (n=71) of cases during reinfection (Fig 3). Out of
207 the total studies, reports of ICU admission and mechanical ventilation was relatively low being
208 0.5% (n=3) and 0.3% (n=2) during first infection, respectively, compared to 1.7% (n=10) and
209 1.6% (n=9) during reinfection, respectively. This was contradictory to a higher number of
210 asymptomatic cases observed in the reinfection phase, implicating for a possible need of an
211 Individual Patient Data (IPD) analysis in future studies.

212 Comparable odds of symptomatic presentation (OR:0.93, 95%CI: 0.74-1.17) and management
213 (OR:0.90, 95%CI: 0.63-1.29) were observed in the first infection compared to reinfection when
214 meta-analyzed, as shown in Fig 2 and Fig 3. Although a higher event of management was
215 observed in the first infection, due to the individual weight of the studies, the overall OR
216 favored first infection and was less than 1.

217 **Outcomes of first infection and reinfection**

218 Complete recovery rate after reinfection stood at 97.9% (565 cases) with a total of 10 (1.8%)
219 deaths. The outcome status was unknown for 2 cases (0.3%) (S2 Table). The eight expired cases

220 were elderly (72-91 years old; 1 male and 7 females) and 2 cases were middle-aged adults (44
221 and 54 years old; both males). Seven cases had comorbidities involving multiple organ systems
222 whilst three suffered from hypertension and the remaining one had an underlying malignancy.
223 Respiratory failure was the most common cause of death (Seven out of ten deaths).

224 **Pediatric (0-19 years) reinfection cases**

225 Out of 577 cases, disaggregated data for 24 pediatric (0-18 years) cases was available.
226 Disaggregation reported positive contact histories in 7 cases (29.2%) with only 1 (4.2%)
227 reporting a comorbidity. A total of 7 cases (29.2%) were asymptomatic followed by fever (n= 4,
228 16.7%) and cough (n= 3, 12.5%) in first infection whereas during reinfection, asymptomatic
229 presentation (n= 7, 29.2%) was followed by cough (n= 4, 16.7%) and then fever (n= 3, 12.5%).
230 With 9 abnormal chest X-ray findings (37.5%), the most frequently used management
231 modalities during first infection and reinfection were anti-viral (n=12) and traditional Chinese
232 Medicine (n=12), respectively. All patient outcomes were reported as recovered.

233 **Quality assessment of included studies**

234 Seventy-two studies were determined to be of good quality while nine studies were of fair
235 quality (S3 Table). Studies were primarily downgraded for unclear study objectives[63],
236 incomplete case definition[16, 28, 48, 66, 67, 70, 77, 83], non-consecutive subject
237 recruitment[19, 27, 30, 34, 38, 39, 44-46, 49, 71, 79, 80, 86, 90], incomparable subjects[79],
238 inadequate length of follow-up[43, 63], inadequate description of statistical methods[39, 46,
239 80] and inadequate description of results[39, 78]. The most common cause for downgrading
240 studies was non-consecutive recruitment which raised concerns that the included sample could

241 be biased towards a more severe presentation or included more individuals undergoing routine
242 screening.

243 **Discussion**

244 Both the developing and developed world are still battling the spread of COVID-19. A major
245 concern that needs to be addressed is the appearance of reinfections in previously recovered
246 COVID-19 patients.

247 Our review is the first, and largest, systematic review covering COVID-19 reinfection cases from
248 over 22 countries, raising questions concerning vaccination and exploring a specific set of
249 determinants that can facilitate reinfection in recovered individuals. Similar systematic reviews
250 on COVID-19 reinfection have been conducted previously[92, 93] but none of those studies, or
251 any conducted so far in the literature, have been as extensive as this review in terms of
252 analyzing the clinical information between first infection and reinfection whilst covering a wide
253 range of international and regional databases. One of the major strengths of this review is the
254 substantial timeframe that it covers: January 2020 to March 2021, spanning a total of 81 studies
255 with a widespread distribution of High-Income Countries (HICs) and LMICs to differentiate
256 features of reinfection cases as per different settings. In addition, adult cases were separated
257 from pediatric cases to differentiate between clinical features and identify the optimal
258 treatment management strategies as per varying age groups. Furthermore, case reports and
259 case series included in our study were quality assessed with 72 out of 81 studies reported to be
260 of good quality. An analysis of only pediatric reinfection cases was also conducted in this
261 review. Good prognosis and lower morbidity were reported in the pediatric cases, similar to the

262 general COVID-19 disease course in the pediatric population[94]. Therefore, we suggest public
263 health campaigns targeting people of younger age as they are at similar risk of reinfection as
264 adults, to ensure elimination of complacency and enforcement of protective measures, such as
265 face masks and social distancing.

266 A broad distribution was seen amongst severity of first infection compared to reinfection as
267 well as management and number of symptomatic cases. The most reported clinical symptoms
268 in our review were fever (41.4%) and cough (34.8%) in first infection with a frequency of 36.4%
269 cases with fever and 34.8% cases with cough in reinfection, respectively. These findings are
270 similar to a trend observed in the review on reinfections by Gidari et al.[95] In addition, the
271 number of asymptomatic cases in our review increased from 9.2% in first infection to 31.9% in
272 second infection, similar to findings reported in the review by Gidari et al[95]. On the contrary,
273 a higher requirement of ICU admission and mechanical ventilation was observed during
274 reinfection in our review. A meta-analysis analysis of 123 cases by Vanca et al[96] showed that
275 the second episode of SARS-COV-2 infection is more severe than the first if it happens within 60
276 days of the first positive PCR. This deems the necessity of IPD analysis as many of the larger
277 case series report more severe cases which might skew the overall findings. A total of 10 deaths
278 were reported in this review, all amongst reinfection cases. In all 10 cases, several
279 comorbidities were present and all patients who were classified as the most severe were of
280 older age, a similar trend seen in a study by Wang et al.[97] Most of these patients died due to
281 respiratory complications; similar effects of these comorbidities can be seen in other
282 respiratory illnesses such as MERS-CoV[98]. The results from this review suggest that
283 comorbidities and age play a major role in the outcome of critical patients.

284 The time duration between first infection and reinfection has been a source of debate. Alinaghi
285 et al. in their systematic review[93] estimated that antibodies from natural infection lasted 40
286 days, after which the chances of reinfection increased. The average time duration between first
287 infection and reinfection in our review was 63.6 days. Wang et al. in their review noted it to be
288 76 days[99] whereas Manish et al. in their review[100] observed a lengthier duration of median
289 113.5 days. This variation in time duration outlines the need for vigilance when it comes to
290 COVID-19 reinfection, especially considering waning antibodies.

291 Another observation made in our review was differences in the presence of antibodies during
292 first infection and reinfection. A recently published systematic review looked at antibody
293 response following SARS-COV-2 infection across multiple studies[101]. They noted that 80% of
294 patients developed IgM antibodies with antibodies being detected after a mean period of 7
295 days and declining after 27 days, and 95% of patients developed IgG antibodies with antibodies
296 being detectable after a mean period of 12 days and started declining after 60 days. Likewise,
297 IgA levels and neutralizing antibodies started declining after 30 days. In our review, 56.0% and
298 63.0% of the patients detected positive for antibodies during first infection and reinfection,
299 respectively. Some evidence suggests that waning antibodies places individuals at a risk for
300 reinfection, which may explain our finding of the time duration of first infection and reinfection
301 being a mean of 63 days. The presence of antibodies could provide a protective role, but it does
302 not specifically prevent reinfection as supported by findings in a systematic review by Piri et
303 al.[102]

304 Whilst our review did not analyze the cause of reinfection being due to different variants, they
305 cannot be excluded. A review by Wang et al.[99] concluded that previous COVID-19 reinfection

306 did not confer total immunity and a second infection by a different variant was possible with
307 the second infection being more severe than the first. Even though most of the studies in our
308 review predated the announcements of the new variants, however, given the ability of the virus
309 to mutate at a rapid pace, some reinfection cases reported in our study could be due to the
310 variants which would have resulted in more severity of reinfection. Whether waning antibodies
311 or new variants were the source of reinfection is a question that should be explored further in
312 future studies.

313 A recent systematic review by Azam et al. looked at the incidence of SARS-COV-2 positivity in
314 patients who had recovered from COVID-19 [103]. They noted that younger patients and those
315 with a longer initial infection were more likely to have recurrent positivity. A similar systematic
316 review by Manish et al. on the assessment of SARS-COV-2 mutations in reinfections and
317 persistent infections[100] noted it to be challenging to differentiate between reinfection and
318 persistent recurrent infection, concluding that the former happened in immunocompetent
319 individuals and the latter happened in immunocompromised individuals. Furthermore, this
320 phenomenon was associated with a faster viral evolution and mutation resulting in the creation
321 of new variants. Lastly, another systematic review by Hoang on the risk factors associated with
322 re-positive viral RNA after recovery from COVID-19 [104] postulated that the re-positive viral
323 RNA seen in their review likely added to the evidence that viral relapse was a cause of COVID-
324 19 recurrence.

325 This review has some limitations, such as the small sample sizes analyzed from each country
326 except for China that had 73% (n=423) of the total included cases. The majority of these cases
327 were reported from Wuhan or the Hubei province, where the gross domestic product per

328 capita is less than half of that of Beijing and Shanghai[105] . Therefore, the findings of studies
329 from China may be generalizable to the socioeconomic and health development status of other
330 middle-income countries and not to high-income nations. This review can be improved by
331 sampling larger series and including IPD, if available, to predict the outcome of COVID-19 illness
332 based off epidemiological trends dramatically reducing hospitalization time, given the lack of
333 sufficient healthcare resources in low-middle income countries. Therefore, a selection bias
334 remains when considering LMICs where admitted hospital patients could be in a more critical
335 state reporting a higher mortality rate.

336 Our review on reinfections in COVID-19 also comes at a pertinent time as countries, especially
337 the developing world, suffer a repeated wave of infection[106]. At this time, public health
338 initiatives aimed at removing complacency are the need of hour, and one of the key messages
339 that needs to be given is that reinfection is a reality and vaccines along with social distancing
340 remain the key in fighting the pandemic. A recently published online longitudinal survey [107]
341 in 23 countries of high, middle and low income, across 4 continents with over 1 million
342 participants provides hope in this regard, as it identified that the intention to vaccinate
343 amongst the general public is at an all-time high, with the major issue not being vaccine
344 hesitancy but a shortage of vaccines. A recent report of a 4 month surveillance of mass
345 immunization in Israel [108] notes two doses of the Pfizer BioNTech mRNA COVID-19 vaccine to
346 be highly effective (95.3%; 95% CI 94.9–95.7) against SARS-CoV-2 infection and mitigated
347 COVID-19-related hospitalizations, severe disease, and death, including those caused by
348 variants including the B.1.1.7 SARS-CoV-2. Whilst the world is still under process of getting
349 vaccinated, data needs to be collected on patients in the long run to analyze whether

350 vaccination has any correlation with reinfection cases and further investigate the average time
351 needed by the various vaccines to achieve their desired efficacies. We hope that governments
352 across the world seize this moment and take steps to ensure equitable distribution of vaccines
353 so that the world can finally step out of the long shadow cast by the COVID-19 pandemic.

354 **Conclusion**

355 COVID-19 first infections and reinfections observe a similar clinical spectrum and management
356 regimen with a slightly higher severity reported during reinfection in the form of requirement
357 for mechanical ventilation and ICU admission. There lies a need for much closer scrutiny of
358 reinfections globally with individual patient data analysis to derive determinants of reinfection
359 incidence and disposition to a severe infection.

360 **Acknowledgements:** None.

361 **References**

362 1. COVID-19 Dashboard [Internet]. Johns Hopkins University. 2021 [cited 20th May 2021].

363 Available from: <https://coronavirus.jhu.edu/map.html>.

364 2. Fergie J, Srivastava A. Immunity to SARS-CoV-2: Lessons Learned. *Front Immunol.*

365 2021;12:654165. Epub 2021/04/06. doi: 10.3389/fimmu.2021.654165. PubMed PMID:

366 33815415; PubMed Central PMCID: PMC8018176.

367 3. Costa AOC, Neto HdCA, Nunes APL, de Castro RD, de Almeida RN. COVID-19: Is

368 reinfection possible? *EXCLI Journal.* 2021;20:522-36.

369 4. Khoshkam Z, Aftabi Y, Stenvinkel P, Paige Lawrence B, Rezaei MH, Ichihara G, et al.

370 Recovery scenario and immunity in COVID-19 disease: A new strategy to predict the potential of

- 371 reinfection. *J Adv Res.* 2021. Epub 2021/02/02. doi: 10.1016/j.jare.2020.12.013. PubMed PMID:
372 33520309; PubMed Central PMCID: PMC7832464.
- 373 5. Prevost J, Finzi A. The great escape? SARS-CoV-2 variants evading neutralizing
374 responses. *Cell Host Microbe.* 2021;29(3):322-4. Epub 2021/03/12. doi:
375 10.1016/j.chom.2021.02.010. PubMed PMID: 33705702; PubMed Central PMCID:
376 PMC7945862.
- 377 6. Wang Z, Schmidt F, Weisblum Y, Muecksch F, Barnes CO, Finkin S, et al. mRNA vaccine-
378 elicited antibodies to SARS-CoV-2 and circulating variants. *Nature.* 2021. Epub 2021/02/11. doi:
379 10.1038/s41586-021-03324-6. PubMed PMID: 33567448.
- 380 7. CDC. Reinfection with COVID-19. [https://www.cdc.gov/coronavirus/2019-ncov/your-](https://www.cdc.gov/coronavirus/2019-ncov/your-health/reinfection.html)
381 [health/reinfection.html](https://www.cdc.gov/coronavirus/2019-ncov/your-health/reinfection.html).2020.
- 382 8. Tillett RL, Sevinsky JR, Hartley PD, Kerwin H, Crawford N, Gorzalski A, et al. Genomic
383 evidence for reinfection with SARS-CoV-2: a case study. *Lancet Infect Dis.* 2021;21(1):52-8. Epub
384 2020/10/16. doi: 10.1016/S1473-3099(20)30764-7. PubMed PMID: 33058797; PubMed Central
385 PMCID: PMC7550103.
- 386 9. Iwasaki A. What reinfections mean for COVID-19. *The Lancet Infectious Diseases.*
387 2021;21(1):3-5. doi: 10.1016/s1473-3099(20)30783-0.
- 388 10. Gomez CE, Perdiguero B, Esteban M. Emerging SARS-CoV-2 Variants and Impact in
389 Global Vaccination Programs against SARS-CoV-2/COVID-19. *Vaccines (Basel).* 2021;9(3). Epub
390 2021/04/04. doi: 10.3390/vaccines9030243. PubMed PMID: 33799505; PubMed Central
391 PMCID: PMC7999234.

- 392 11. Welfare MoHAF. Genome Sequencing by INSACOG shows variants of concern and a
393 Novel variant in India. <https://pib.gov.in/PressReleaselframePage.aspx?PRID=1707177>; PIB
394 Delhi; 2021.
- 395 12. Abdallah H, Porterfield F, Fajgenbaum D. Symptomatic relapse and long-term sequelae
396 of COVID-19 in a previously healthy 30-year-old man. *BMJ Case Rep.* 2020;13(12):e239825-e.
397 Epub 2020/12/16. doi: 10.1136/bcr-2020-239825. PubMed PMID: 33318288; PubMed Central
398 PMCID: PMCPMC7736956.
- 399 13. Adrielle Dos Santos L, Filho PGG, Silva AMF, Santos JVG, Santos DS, Aquino MM, et al.
400 Recurrent COVID-19 including evidence of reinfection and enhanced severity in thirty Brazilian
401 healthcare workers. *J Infect.* 2021;82(3):399-406. Epub 2021/02/17. doi:
402 10.1016/j.jinf.2021.01.020. PubMed PMID: 33589297; PubMed Central PMCID:
403 PMCPMC7880834.
- 404 14. Ak R, Yilmaz E, Seyhan AU, Doganay F. Recurrence of COVID-19 Documented with RT-
405 PCR. *J Coll Physicians Surg Pak.* 2021;30(1):S26-S8. Epub 2021/03/03. doi:
406 10.29271/jcpsp.2021.01.S26. PubMed PMID: 33650420.
- 407 15. Ali AM, Ali KM, Fatah MH, Tawfeeq HM, Rostam HM. SARS-CoV-2 Reinfection in Patients
408 Negative for Immunoglobulin G Following Recovery from COVID-19. *medRxiv*; 2020. p.
409 2020.11.20.20234385-2020.11.20.
- 410 16. Alonso FOM, Sabino BD, Guimaraes M, Varella RB. Recurrence of SARS-CoV-2 infection
411 with a more severe case after mild COVID-19, reversion of RT-qPCR for positive and late
412 antibody response: Case report. *J Med Virol.* 2021;93(2):655-6. Epub 2020/08/17. doi:
413 10.1002/jmv.26432. PubMed PMID: 32797634; PubMed Central PMCID: PMCPMC7436374.

- 414 17. An J, Liao X, Xiao T, Qian S, Yuan J, Ye H, et al. Clinical characteristics of recovered
415 COVID-19 patients with re-detectable positive RNA test. *Ann Transl Med.* 2020;8(17):1084.
416 Epub 2020/11/05. doi: 10.21037/atm-20-5602. PubMed PMID: 33145303; PubMed Central
417 PMCID: PMCPMC7575971.
- 418 18. Arteaga-Livias K, Panduro-Correa V, Pinzas-Acosta K, Perez-Abad L, Pecho-Silva S,
419 Espinoza-Sanchez F, et al. COVID-19 reinfection? A suspected case in a Peruvian patient. *Travel*
420 *Med Infect Dis.* 2021;39(Jan-Feb 2021):101947. Epub 2020/12/12. doi:
421 10.1016/j.tmaid.2020.101947. PubMed PMID: 33307196; PubMed Central PMCID:
422 PMCPMC7723440.
- 423 19. Atici S, Ek OF, Yildiz MS, Sikgenc MM, Guzel E, Soysal A. Symptomatic recurrence of
424 SARS-CoV-2 infection in healthcare workers recovered from COVID-19. *J Infect Dev Ctries.*
425 2021;15(1):69-72. Epub 2021/02/12. doi: 10.3855/jidc.14305. PubMed PMID: 33571147.
- 426 20. Bellanti F, Lo Buglio A, Custodero G, Barbera L, Minafra G, Montrano M, et al. Fatal
427 relapse of COVID-19 after recovery? A case report of an older Italian patient. *J Infect.*
428 2021;82(1):e49-e51. Epub 2020/12/20. doi: 10.1016/j.jinf.2020.12.009. PubMed PMID:
429 33340595; PubMed Central PMCID: PMCPMC7834308.
- 430 21. Bellesso M, Bruniera FR, Trunkel AT, Nicodemo IP. Second COVID-19 infection in a
431 patient with multiple myeloma in Brazil - reinfection or reactivation? *Hematol Transfus Cell*
432 *Ther.* 2021;43(1):109-11. Epub 2021/01/12. doi: 10.1016/j.htct.2020.12.002. PubMed PMID:
433 33423984; PubMed Central PMCID: PMCPMC7837121.

- 434 22. Bongiovanni M. COVID-19 reinfection in a healthcare worker. *J Med Virol*.
435 2020;jmv.26565-jmv. Epub 2020/09/30. doi: 10.1002/jmv.26565. PubMed PMID: 32990954;
436 PubMed Central PMCID: PMC7537129.
- 437 23. Bonifacio LP, Pereira APS, Araujo D, Balbao V, Fonseca B, Passos ADC, et al. Are SARS-
438 CoV-2 reinfection and Covid-19 recurrence possible? a case report from Brazil. *Rev Soc Bras*
439 *Med Trop*. 2020;53:e20200619. Epub 2020/09/24. doi: 10.1590/0037-8682-0619-2020.
440 PubMed PMID: 32965458; PubMed Central PMCID: PMC7508196.
- 441 24. Cao H, Ruan L, Liu J, Liao W. The clinical characteristic of eight patients of COVID-19 with
442 positive RT-PCR test after discharge. *J Med Virol*. 2020;92(10):2159-64. Epub 2020/05/16. doi:
443 10.1002/jmv.26017. PubMed PMID: 32410245; PubMed Central PMCID: PMC7272974.
- 444 25. Chan PKS, Lui G, Hachim A, Ko RLW, Boon SS, Li T, et al. Serologic Responses in Healthy
445 Adult with SARS-CoV-2 Reinfection, Hong Kong, August 2020. *Emerg Infect Dis*.
446 2020;26(12):3076-8. Epub 2020/10/23. doi: 10.3201/eid2612.203833. PubMed PMID:
447 33089772; PubMed Central PMCID: PMC7706979.
- 448 26. Chen D, Xu W, Lei Z, Huang Z, Liu J, Gao Z, et al. Recurrence of positive SARS-CoV-2 RNA
449 in COVID-19: A case report. *Int J Infect Dis*. 2020;93(Apr):297-9. Epub 2020/03/10. doi:
450 10.1016/j.ijid.2020.03.003. PubMed PMID: 32147538; PubMed Central PMCID:
451 PMC7129213.
- 452 27. Chen J, Xu X, Hu J, Chen Q, Xu F, Liang H, et al. Clinical course and risk factors for
453 recurrence of positive SARS-CoV-2 RNA: a retrospective cohort study from Wuhan, China. *Aging*
454 (Albany NY). 2020;12(17):16675-89. Epub 2020/09/11. doi: 10.18632/aging.103795. PubMed
455 PMID: 32909961; PubMed Central PMCID: PMC7521537.

- 456 28. Colson P, Finaud M, Levy N, Lagier JC, Raoult D. Evidence of SARS-CoV-2 re-infection
457 with a different genotype. *J Infect.* 2021;82(4):84-123. Epub 2020/11/19. doi:
458 10.1016/j.jinf.2020.11.011. PubMed PMID: 33207255; PubMed Central PMCID:
459 PMCPMC7666873.
- 460 29. Coppola A, Annunziata A, Carannante N, Di Spirito V, Fiorentino G. Late Reactivation of
461 SARS-CoV-2: A Case Report. *Front Med (Lausanne).* 2020;7:531. Epub 2020/09/26. doi:
462 10.3389/fmed.2020.00531. PubMed PMID: 32974374; PubMed Central PMCID:
463 PMCPMC7468504.
- 464 30. de Brito CAA, Lima PMA, de Brito MCM, de Oliveira DB. Second Episode of COVID-19 in
465 Health Professionals: Report of Two Cases. *Int Med Case Rep J.* 2020;13(Oct):471-5. Epub
466 2020/10/17. doi: 10.2147/IMCRJ.S277882. PubMed PMID: 33061670; PubMed Central PMCID:
467 PMCPMC7537988.
- 468 31. Dou C, Xie X, Peng Z, Tang H, Jiang Z, Zhong Z, et al. A case presentation for positive
469 SARS-CoV-2 RNA recurrence in a patient with a history of type 2 diabetes that had recovered
470 from severe COVID-19. *Diabetes Res Clin Pract.* 2020;166:108300. Epub 2020/07/15. doi:
471 10.1016/j.diabres.2020.108300. PubMed PMID: 32663490; PubMed Central PMCID:
472 PMCPMC7354258.
- 473 32. Du HW, Chen JN, Pan XB, Chen XL, Yixian Z, Fang SF, et al. Prevalence and outcomes of
474 re-positive nucleic acid tests in discharged COVID-19 patients. *Eur J Clin Microbiol Infect Dis.*
475 2021;40(2):413-7. Epub 2020/09/01. doi: 10.1007/s10096-020-04024-1. PubMed PMID:
476 32865669; PubMed Central PMCID: PMCPMC7456660.

- 477 33. Duggan NM, Ludy SM, Shannon BC, Reisner AT, Wilcox SR. Is novel coronavirus 2019
478 reinfection possible? Interpreting dynamic SARS-CoV-2 test results. *Am J Emerg Med*.
479 2021;39:256 e1- e3. Epub 2020/07/25. doi: 10.1016/j.ajem.2020.06.079. PubMed PMID:
480 32703607; PubMed Central PMCID: PMC7335242.
- 481 34. Fu W, Chen Q, Wang T. Letter to the Editor: Three cases of redetectable positive SARS-
482 CoV-2 RNA in recovered COVID-19 patients with antibodies. *J Med Virol*. 2020;92(11):2298-301.
483 Epub 2020/05/06. doi: 10.1002/jmv.25968. PubMed PMID: 32369214; PubMed Central PMCID:
484 PMC7267393.
- 485 35. Gao G, Zhu Z, Fan L, Ye S, Huang Z, Shi Q, et al. Absent immune response to SARS-CoV-2
486 in a 3-month recurrence of coronavirus disease 2019 (COVID-19) case. *Infection*. 2021;49(1):57-
487 61. Epub 2020/07/30. doi: 10.1007/s15010-020-01485-6. PubMed PMID: 32725596; PubMed
488 Central PMCID: PMC7386381.
- 489 36. Goldman JD, Wang K, Röltgen K, Nielsen SCA, Roach JC, Naccache SN, et al. Reinfection
490 with SARS-CoV-2 and Failure of Humoral Immunity: A case report. *medRxiv*; 2020.
- 491 37. Gousseff M, Penot P, Gallay L, Batisse D, Benech N, Bouiller K, et al. Clinical recurrences
492 of COVID-19 symptoms after recovery: Viral relapse, reinfection or inflammatory rebound? *J*
493 *Infect*. 2020;81(5):816-46. Epub 2020/07/04. doi: 10.1016/j.jinf.2020.06.073. PubMed PMID:
494 32619697; PubMed Central PMCID: PMC7326402 interest to declare regarding this subject.
495 This work had no financial support.
- 496 38. Gupta V, Bhojar RC, Jain A, Srivastava S, Upadhyay R, Imran M, et al. Asymptomatic
497 reinfection in two healthcare workers from India with genetically distinct SARS-CoV-2. *Clin*

- 498 Infect Dis. 2020. Epub 2020/09/24. doi: 10.1093/cid/ciaa1451. PubMed PMID: 32964927;
499 PubMed Central PMCID: PMC7543380.
- 500 39. Habibzadeh P, Sajadi MM, Emami A, Karimi MH, Yadollahie M, Kucheki M, et al. Rate of
501 re-positive RT-PCR test among patients recovered from COVID-19. *Biochem Med (Zagreb)*.
502 2020;30(3):030401. Epub 2020/08/11. doi: 10.11613/BM.2020.030401. PubMed PMID:
503 32774117; PubMed Central PMCID: PMC7394260.
- 504 40. Hanif M, Haider MA, Ali MJ, Naz S, Sundas F. Reinfection of COVID-19 in Pakistan: A First
505 Case Report. *Cureus*. 2020;12(10):e11176. Epub 2020/12/03. doi: 10.7759/cureus.11176.
506 PubMed PMID: 33262913; PubMed Central PMCID: PMC7689968.
- 507 41. Harrington D, Kele B, Pereira S, Couto-Parada X, Riddell A, Forbes S, et al. Confirmed
508 Reinfection with SARS-CoV-2 Variant VOC-202012/01. *Clin Infect Dis*. 2021. Epub 2021/01/10.
509 doi: 10.1093/cid/ciab014. PubMed PMID: 33421056; PubMed Central PMCID:
510 PMC7929017.
- 511 42. He S, Sun W, Zhou K, Hu M, Liu C, Xie L, et al. Clinical Characteristics Analysis of the “Re-
512 positive” Discharged COVID-19 Pneumonia Patients in Wuhan, China. 2020. doi:
513 10.21203/rs.3.rs-28667/v1.
- 514 43. Huang J, Zheng L, Li Z, Hao S, Ye F, Chen J, et al. Recurrence of SARS-CoV-2 PCR positivity
515 in COVID-19 patients: A single center experience and potential implications. *medRxiv*; 2020. p.
516 2020.05.06.20089573-2020.05.06.
- 517 44. Kapoor R, Nair RK, Nayan N, Bhalla S, Singh J. Reinfection or Reactivation of Coronavirus-
518 19 in Patients with Hematologic Malignancies: Case Report Series. *SN Compr Clin Med*.

- 519 2021;3(2):1-5. Epub 2021/02/16. doi: 10.1007/s42399-021-00790-x. PubMed PMID: 33585797;
520 PubMed Central PMCID: PMC7873512.
- 521 45. Lafaie L, Celarier T, Goethals L, Pozzetto B, Grange S, Ojardias E, et al. Recurrence or
522 Relapse of COVID-19 in Older Patients: A Description of Three Cases. *J Am Geriatr Soc*.
523 2020;68(10):2179-83. Epub 2020/07/09. doi: 10.1111/jgs.16728. PubMed PMID: 32638347;
524 PubMed Central PMCID: PMC7361461.
- 525 46. Lan L, Xu D, Ye G, Xia C, Wang S, Li Y, et al. Positive RT-PCR Test Results in Patients
526 Recovered From COVID-19. *JAMA*. 2020;323(15):1502-3. Epub 2020/02/28. doi:
527 10.1001/jama.2020.2783. PubMed PMID: 32105304; PubMed Central PMCID:
528 PMC7047852.
- 529 47. Lancman G, Mascarenhas J, Bar-Natan M. Severe COVID-19 virus reactivation following
530 treatment for B cell acute lymphoblastic leukemia. *J Hematol Oncol*. 2020;13(1):131. Epub
531 2020/10/04. doi: 10.1186/s13045-020-00968-1. PubMed PMID: 33008453; PubMed Central
532 PMCID: PMC7531062.
- 533 48. Larson D, Brodniak SL, Voegtly LJ, Cer RZ, Glang LA, Malagon FJ, et al. A Case of Early Re-
534 infection with SARS-CoV-2. *Clin Infect Dis*. 2020. Epub 2020/09/20. doi: 10.1093/cid/ciaa1436.
535 PubMed PMID: 32949240; PubMed Central PMCID: PMC7543357.
- 536 49. Li J, Wei X, Tian W, Zou J, Wang Y, Xue W, et al. Clinical features of discharged COVID-19
537 patients with an extended SARS-CoV-2 RNA positive signal in respiratory samples. *Virus Res*.
538 2020;286:198047. Epub 2020/06/12. doi: 10.1016/j.virusres.2020.198047. PubMed PMID:
539 32522535; PubMed Central PMCID: PMC7833058.

- 540 50. Li XJ, Zhang ZW, Zong ZY. A case of a readmitted patient who recovered from COVID-19
541 in Chengdu, China. *Crit Care*. 2020;24(1):152. Epub 2020/04/18. doi: 10.1186/s13054-020-
542 02877-8. PubMed PMID: 32299477; PubMed Central PMCID: PMC7160612.
- 543 51. Li Y, Hu Y, Yu Y, Zhang X, Li B, Wu J, et al. Positive result of Sars-Cov-2 in faeces and
544 sputum from discharged patients with COVID-19 in Yiwu, China. *J Med Virol*. 2020;92(10):1938-
545 47. Epub 2020/04/21. doi: 10.1002/jmv.25905. PubMed PMID: 32311109; PubMed Central
546 PMCID: PMC7264799.
- 547 52. Ling Y, Xu SB, Lin YX, Tian D, Zhu ZQ, Dai FH, et al. Persistence and clearance of viral RNA
548 in 2019 novel coronavirus disease rehabilitation patients. *Chin Med J (Engl)*. 2020;133(9):1039-
549 43. Epub 2020/03/03. doi: 10.1097/CM9.0000000000000774. PubMed PMID: 32118639;
550 PubMed Central PMCID: PMC7147278.
- 551 53. Liu F, Cai ZB, Huang JS, Yu WY, Niu HY, Zhang Y, et al. Positive SARS-CoV-2 RNA recurs
552 repeatedly in a case recovered from COVID-19: dynamic results from 108 days of follow-up.
553 *Pathog Dis*. 2020;78(4):31-. Epub 2020/06/28. doi: 10.1093/femspd/ftaa031. PubMed PMID:
554 32592396; PubMed Central PMCID: PMC7337794.
- 555 54. Loconsole D, Passerini F, Palmieri VO, Centrone F, Sallustio A, Pugliese S, et al.
556 Recurrence of COVID-19 after recovery: a case report from Italy. *Infection*. 2020;48(6):965-7.
557 Epub 2020/05/18. doi: 10.1007/s15010-020-01444-1. PubMed PMID: 32415334; PubMed
558 Central PMCID: PMC7228864.
- 559 55. Luo A. Positive SARS-Cov-2 test in a woman with COVID-19 at 22 days after hospital
560 discharge: A case report. *Journal of Traditional Chinese Medical Sciences*. 2020;7(4):413-7. doi:
561 10.1016/j.jtcms.2020.04.001.

- 562 56. Mei Q, Li J, Du R, Yuan X, Li M, Li J. Assessment of patients who tested positive for
563 COVID-19 after recovery. *Lancet Infect Dis.* 2020;20(9):1004-5. Epub 2020/07/10. doi:
564 10.1016/S1473-3099(20)30433-3. PubMed PMID: 32645295; PubMed Central PMCID:
565 PMC7338012.
- 566 57. Moore JL, Ganapathiraju PV, Kurtz CP, Wainscoat B. A 63-Year-Old Woman with a
567 History of Non-Hodgkin Lymphoma with Persistent SARS-CoV-2 Infection Who Was
568 Seronegative and Treated with Convalescent Plasma. *Am J Case Rep.* 2020;21:e927812. Epub
569 2020/10/04. doi: 10.12659/AJCR.927812. PubMed PMID: 33009361; PubMed Central PMCID:
570 PMC7542548.
- 571 58. Mulder M, van der Vegt D, Oude Munnink BB, GeurtsvanKessel CH, van de Bovenkamp J,
572 Sikkema RS, et al. Reinfection of SARS-CoV-2 in an immunocompromised patient: a case report.
573 *Clin Infect Dis.* 2020. Epub 2020/10/13. doi: 10.1093/cid/ciaa1538. PubMed PMID: 33043962;
574 PubMed Central PMCID: PMC7665355.
- 575 59. Nachmias V, Fusman R, Mann S, Koren G. The first case of documented Covid-19
576 reinfection in Israel. *IDCases.* 2020;22:e00970. Epub 2020/10/09. doi:
577 10.1016/j.idcr.2020.e00970. PubMed PMID: 33029476; PubMed Central PMCID:
578 PMC7528892.
- 579 60. Novoa W, Miller H, Mattar S, Faccini-Martinez AA, Rivero R, Serrano-Coll H. A first
580 probable case of SARS-CoV-2 reinfection in Colombia. *Ann Clin Microbiol Antimicrob.*
581 2021;20(1):7. Epub 2021/01/14. doi: 10.1186/s12941-020-00413-8. PubMed PMID: 33435982;
582 PubMed Central PMCID: PMC7802059.

- 583 61. Pan L, Wang R, Yu N, Hu C, Yan J, Zhang X, et al. Clinical characteristics of re-hospitalized
584 COVID-19 patients with recurrent positive SARS-CoV-2 RNA: a retrospective study. *Eur J Clin*
585 *Microbiol Infect Dis.* 2021. Epub 2021/01/16. doi: 10.1007/s10096-020-04151-9. PubMed
586 PMID: 33447913; PubMed Central PMCID: PMC7808928.
- 587 62. Parry J. Covid-19: Hong Kong scientists report first confirmed case of reinfection. *BMJ.*
588 2020;370:m3340. Epub 2020/08/28. doi: 10.1136/bmj.m3340. PubMed PMID: 32847834.
- 589 63. Patrocinio de Jesus R, Silva R, Aliyeva E, Lopes L, Portugalyan M, Antunes L, et al.
590 Reactivation of SARS-CoV-2 after Asymptomatic Infection while on High-Dose Corticosteroids.
591 Case Report. *SN Compr Clin Med.* 2020;2(11):1-4. Epub 2020/10/13. doi: 10.1007/s42399-020-
592 00548-x. PubMed PMID: 33043249; PubMed Central PMCID: PMC7531809.
- 593 64. Prado-Vivar B, Becerra-Wong M, Guadalupe JJ, Marquez S, Gutierrez B, Rojas-Silva P, et
594 al. A case of SARS-CoV-2 reinfection in Ecuador. *Lancet Infect Dis.* 2020. Epub 2020/11/27. doi:
595 10.1016/S1473-3099(20)30910-5. PubMed PMID: 33242475; PubMed Central PMCID:
596 PMC7833993.
- 597 65. Salcin S, Fontem F. Recurrent SARS-CoV-2 infection resulting in acute respiratory distress
598 syndrome and development of pulmonary hypertension: A case report. *Respir Med Case Rep.*
599 2021;33:101314. Epub 2020/12/15. doi: 10.1016/j.rmcr.2020.101314. PubMed PMID:
600 33312856; PubMed Central PMCID: PMC7718582.
- 601 66. Selhorst P, Van Ierssel S, Michiels J, Marien J, Bartholomeeusen K, Dirinck E, et al.
602 Symptomatic SARS-CoV-2 reinfection of a health care worker in a Belgian nosocomial outbreak
603 despite primary neutralizing antibody response. *Clin Infect Dis.* 2020. Epub 2020/12/15. doi:
604 10.1093/cid/ciaa1850. PubMed PMID: 33315049; PubMed Central PMCID: PMC7799230.

- 605 67. Selvaraj V, Herman K, Dapaah-Afriyie K. Severe, Symptomatic Reinfection in a Patient
606 with COVID-19. *R I Med J* (2013). 2020;103(10):24-6. Epub 2020/11/12. PubMed PMID:
607 33172223.
- 608 68. Sharma R, Sardar S, Mohammad Arshad A, Ata F, Zara S, Munir W. A Patient with
609 Asymptomatic SARS-CoV-2 Infection Who Presented 86 Days Later with COVID-19 Pneumonia
610 Possibly Due to Reinfection with SARS-CoV-2. *Am J Case Rep*. 2020;21:e927154. Epub
611 2020/12/02. doi: 10.12659/AJCR.927154. PubMed PMID: 33257644; PubMed Central PMCID:
612 PMC7718490.
- 613 69. Sicsic I, Jr., Chacon AR, Zaw M, Ascher K, Abreu A, Chediak A. A case of SARS-CoV-2
614 reinfection in a patient with obstructive sleep apnea managed with telemedicine. *BMJ Case*
615 *Rep*. 2021;14(2):240496-. Epub 2021/02/03. doi: 10.1136/bcr-2020-240496. PubMed PMID:
616 33526540; PubMed Central PMCID: PMC7852971.
- 617 70. Song KH, Kim DM, Lee H, Ham SY, Oh SM, Jeong H, et al. Dynamics of viral load and anti-
618 SARS-CoV-2 antibodies in patients with positive RT-PCR results after recovery from COVID-19.
619 *Korean J Intern Med*. 2021;36(1):11-4. Epub 2020/09/26. doi: 10.3904/kjim.2020.325. PubMed
620 PMID: 32972123; PubMed Central PMCID: PMC7820639.
- 621 71. Fernandes Valente Takeda C, Moura de Almeida M, Goncalves de Aguiar Gomes R, Cisne
622 Souza T, Alves de Lima Mota M, Pamplona de Goes Cavalcanti L, et al. Case Report: Recurrent
623 Clinical Symptoms of COVID-19 in Healthcare Professionals: A Series of Cases from Brazil. *Am J*
624 *Trop Med Hyg*. 2020;103(5):1993-6. Epub 2020/09/06. doi: 10.4269/ajtmh.20-0893. PubMed
625 PMID: 32888288; PubMed Central PMCID: PMC7646791.

- 626 72. Tian M, Long Y, Hong Y, Zhang X, Zha Y. The treatment and follow-up of 'recurrence'
627 with discharged COVID-19 patients: data from Guizhou, China. *Environ Microbiol.*
628 2020;22(8):3588-92. Epub 2020/07/08. doi: 10.1111/1462-2920.15156. PubMed PMID:
629 32632947; PubMed Central PMCID: PMC7361525.
- 630 73. To KK, Hung IF, Ip JD, Chu AW, Chan WM, Tam AR, et al. COVID-19 re-infection by a
631 phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing.
632 *Clin Infect Dis.* 2020. Epub 2020/08/26. doi: 10.1093/cid/ciaa1275. PubMed PMID: 32840608;
633 PubMed Central PMCID: PMC7499500.
- 634 74. Tomassini S, Kotecha D, Bird PW, Folwell A, Biju S, Tang JW. Setting the criteria for SARS-
635 CoV-2 reinfection - six possible cases. *J Infect.* 2021;82(2):282-327. Epub 2020/08/18. doi:
636 10.1016/j.jinf.2020.08.011. PubMed PMID: 32800801; PubMed Central PMCID:
637 PMC7422822.
- 638 75. Torres DA, Ribeiro L, Riello A, Horovitz DDG, Pinto LFR, Croda J. Reinfection of COVID-19
639 after 3 months with a distinct and more aggressive clinical presentation: Case report. *J Med*
640 *Virool.* 2021;93(4):1857-9. Epub 2020/10/29. doi: 10.1002/jmv.26637. PubMed PMID: 33112002.
- 641 76. Van Elslande J, Vermeersch P, Vandervoort K, Wawina-Bokalanga T, Vanmechelen B,
642 Wollants E, et al. Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct strain. *Clin*
643 *Infect Dis.* 2020. Epub 2020/09/06. doi: 10.1093/cid/ciaa1330. PubMed PMID: 32887979;
644 PubMed Central PMCID: PMC7499557.
- 645 77. Vetter P, Cordey S, Schibler M, Vieux L, Despres L, Laubscher F, et al. Clinical, virologic
646 and immunologic features of a mild case of SARS-CoV-2 reinfection. *Clin Microbiol Infect.*

- 647 2021;21(1):1-. Epub 2021/02/23. doi: 10.1016/j.cmi.2021.02.010. PubMed PMID: 33618012;
648 PubMed Central PMCID: PMC7896115.
- 649 78. West J, Everden S, Nikitas N. A case of COVID-19 reinfection in the UK. *Clin Med (Lond)*.
650 2021;21(1):e52-e3. Epub 2020/12/12. doi: 10.7861/clinmed.2020-0912. PubMed PMID:
651 33303623; PubMed Central PMCID: PMC7850175.
- 652 79. Wu J, Cheng J, Shi X, Liu J, Huang B, Zhao X, et al. Recurrence of SARS-CoV-2 nucleic acid
653 positive test in patients with COVID-19: a report of two cases. *BMC Pulm Med*. 2020;20(1):308.
654 Epub 2020/11/24. doi: 10.1186/s12890-020-01348-8. PubMed PMID: 33225932; PubMed
655 Central PMCID: PMC7681189.
- 656 80. Yadav S, Wadhwa T, Thakkar D, Kapoor R, Rastogi N, Sarma S. Covid19 Reinfection in
657 Two Children with Cancer. *Authorea Preprints*. 2020. doi: 10.22541/au.159986505.57940176.
- 658 81. Yadav SP, Thakkar D, Bhojar RC, Jain A, Wadhwa T, Imran M, et al. Asymptomatic
659 reactivation of SARS-CoV-2 in a child with neuroblastoma characterised by whole genome
660 sequencing. *IDCases*. 2021;23:e01018. Epub 2020/12/09. doi: 10.1016/j.idcr.2020.e01018.
661 PubMed PMID: 33288996; PubMed Central PMCID: PMC7711173.
- 662 82. Ye G, Pan Z, Pan Y, Deng Q, Chen L, Li J, et al. Clinical characteristics of severe acute
663 respiratory syndrome coronavirus 2 reactivation. *J Infect*. 2020;80(5):e14-e7. Epub 2020/03/17.
664 doi: 10.1016/j.jinf.2020.03.001. PubMed PMID: 32171867; PubMed Central PMCID:
665 PMC7102560.
- 666 83. Yoo SY, Lee Y, Lee GH, Kim DH. Reactivation of SARS-CoV-2 after recovery. *Pediatr Int*.
667 2020;62(7):879-81. Epub 2020/05/19. doi: 10.1111/ped.14312. PubMed PMID: 32421910;
668 PubMed Central PMCID: PMC7276786.

- 669 84. Yuan J, Kou S, Liang Y, Zeng J, Pan Y, Liu L. Polymerase Chain Reaction Assays Reverted
670 to Positive in 25 Discharged Patients With COVID-19. *Clin Infect Dis*. 2020;71(16):2230-2. Epub
671 2020/04/09. doi: 10.1093/cid/ciaa398. PubMed PMID: 32266381; PubMed Central PMCID:
672 PMCPMC7184423.
- 673 85. Zayet S, Royer PY, Toko L, Pierron A, Gendrin V, Klopfenstein T. Recurrence of COVID-19
674 after recovery ? A case series in health care workers, France. *Microbes Infect*. 2021:104803.
675 Epub 2021/03/06. doi: 10.1016/j.micinf.2021.104803. PubMed PMID: 33667643; PubMed
676 Central PMCID: PMCPMC7923857.
- 677 86. Zhang B, Liu S, Dong Y, Zhang L, Zhong Q, Zou Y, et al. Positive rectal swabs in young
678 patients recovered from coronavirus disease 2019 (COVID-19). *J Infect*. 2020;81(2):e49-e52.
679 Epub 2020/04/27. doi: 10.1016/j.jinf.2020.04.023. PubMed PMID: 32335176; PubMed Central
680 PMCID: PMCPMC7177113.
- 681 87. Zhao W, Wang Y, Tang Y, Zhao W, Fan Y, Liu G, et al. Characteristics of Children With
682 Reactivation of SARS-CoV-2 Infection After Hospital Discharge. *Clin Pediatr (Phila)*. 2020;59(9-
683 10):929-32. Epub 2020/05/29. doi: 10.1177/0009922820928057. PubMed PMID: 32462940.
- 684 88. Zheng J, Zhou R, Chen F, Tang G, Wu K, Li F, et al. Incidence, clinical course and risk
685 factor for recurrent PCR positivity in discharged COVID-19 patients in Guangzhou, China: A
686 prospective cohort study. *PLoS Negl Trop Dis*. 2020;14(8):e0008648. Epub 2020/09/01. doi:
687 10.1371/journal.pntd.0008648. PubMed PMID: 32866168; PubMed Central PMCID:
688 PMCPMC7505432.
- 689 89. Zheng KI, Wang XB, Jin XH, Liu WY, Gao F, Chen YP, et al. A Case Series of Recurrent Viral
690 RNA Positivity in Recovered COVID-19 Chinese Patients. *J Gen Intern Med*. 2020;35(7):2205-6.

- 691 Epub 2020/04/22. doi: 10.1007/s11606-020-05822-1. PubMed PMID: 32314129; PubMed
692 Central PMCID: PMCPMC7169645.
- 693 90. Zhu H, Fu L, Jin Y, Shao J, Zhang S, Zheng N, et al. Clinical features of COVID-19
694 convalescent patients with re-positive nucleic acid detection. *J Clin Lab Anal.*
695 2020;34(7):e23392. Epub 2020/06/09. doi: 10.1002/jcla.23392. PubMed PMID: 32506726;
696 PubMed Central PMCID: PMCPMC7300578.
- 697 91. Zucman N, Uhel F, Descamps D, Roux D, Ricard JD. Severe reinfection with South African
698 SARS-CoV-2 variant 501Y.V2: A case report. *Clin Infect Dis.* 2021. Epub 2021/02/11. doi:
699 10.1093/cid/ciab129. PubMed PMID: 33566076; PubMed Central PMCID: PMCPMC7929064.
- 700 92. Padda I, Khehra N, Jaferi U, Mosabbeh D, Atwal H, Musaji A, et al. Organ system effects
701 and reinfection of COVID-19: A systematic review. *Journal of Research in Clinical Medicine.*
702 2021;9(1):6-. doi: 10.34172/jrcm.2021.006.
- 703 93. SeyedAlinaghi S, Oliaei S, Kianzad S, Afsahi AM, MohsseniPour M, Barzegary A, et al.
704 Reinfection risk of novel coronavirus (COVID-19): A systematic review of current evidence.
705 *World J Virol.* 2020;9(5):79-90. Epub 2020/12/29. doi: 10.5501/wjv.v9.i5.79. PubMed PMID:
706 33363000; PubMed Central PMCID: PMCPMC7747024.
- 707 94. Irfan O, Muttalib F, Tang K, Jiang L, Lassi ZS, Bhutta Z. Clinical characteristics, treatment
708 and outcomes of paediatric COVID-19: a systematic review and meta-analysis. *Arch Dis Child.*
709 2021. Epub 2021/02/18. doi: 10.1136/archdischild-2020-321385. PubMed PMID: 33593743.
- 710 95. Gidari A, Nofri M, Saccarelli L, Bastianelli S, Sabbatini S, Bozza S, et al. Is recurrence
711 possible in coronavirus disease 2019 (COVID-19)? Case series and systematic review of
712 literature. *Eur J Clin Microbiol Infect Dis.* 2021;40(1):1-12. Epub 2020/10/11. doi:

- 713 10.1007/s10096-020-04057-6. PubMed PMID: 33037944; PubMed Central PMCID:
714 PMCPMC7547550.
- 715 96. Vanca S, Dembrovsky F, Farkas N, Szako L, Teutsch B, Bunduc S, et al. Repeated SARS-
716 CoV-2 Positivity: Analysis of 123 Cases. *Viruses*. 2021;13(3). Epub 2021/04/04. doi:
717 10.3390/v13030512. PubMed PMID: 33808867; PubMed Central PMCID: PMCPMC8003803.
- 718 97. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138
719 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.
720 *JAMA*. 2020;323(11):1061-9. Epub 2020/02/08. doi: 10.1001/jama.2020.1585. PubMed PMID:
721 32031570; PubMed Central PMCID: PMCPMC7042881.
- 722 98. Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory
723 syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. *Int J Infect Dis*.
724 2016;49(Aug):129-33. Epub 2016/06/30. doi: 10.1016/j.ijid.2016.06.015. PubMed PMID:
725 27352628; PubMed Central PMCID: PMCPMC7110556.
- 726 99. Wang J, Kaperak C, Sato T, Sakuraba A. COVID-19 reinfection: A Rapid Systematic Review
727 of Case Reports and Case Series. *medRxiv*. 2021:2021.03.22.21254081. doi:
728 10.1101/2021.03.22.21254081.
- 729 100. Choudhary MC, Crain CR, Qiu X, Hanage W, Li JZ. SARS-CoV-2 Sequence Characteristics
730 of COVID-19 Persistence and Reinfection. *Clin Infect Dis*. 2021;(2021). Epub 2021/04/28. doi:
731 10.1093/cid/ciab380. PubMed PMID: 33906227.
- 732 101. Arkhipova-Jenkins I, Helfand M, Armstrong C, Gean E, Anderson J, Paynter RA, et al.
733 Antibody Response After SARS-CoV-2 Infection and Implications for Immunity : A Rapid Living

- 734 Review. *Ann Intern Med.* 2021. Epub 2021/03/16. doi: 10.7326/M20-7547. PubMed PMID:
735 33721517; PubMed Central PMCID: PMC8025942.
- 736 102. Piri SM, Edalatfar M, Shool S, Jalalian MN, Tavakolpour S. A systematic review on the
737 recurrence of SARS-CoV-2 virus: frequency, risk factors, and possible explanations. *Infect Dis*
738 (Lond). 2021;53(5):315-24. Epub 2021/01/30. doi: 10.1080/23744235.2020.1871066. PubMed
739 PMID: 33508989; PubMed Central PMCID: PMC8025942.
- 740 103. Azam M, Sulistiana R, Ratnawati M, Fibriana AI, Bahrudin U, Widyaningrum D, et al.
741 Recurrent SARS-CoV-2 RNA positivity after COVID-19: a systematic review and meta-analysis.
742 *Sci Rep.* 2020;10(1):20692. Epub 2020/11/28. doi: 10.1038/s41598-020-77739-y. PubMed
743 PMID: 33244060; PubMed Central PMCID: PMC8025942.
- 744 104. Hoang T. Systematic review and meta-analysis of factors associated with re-positive viral
745 RNA after recovery from COVID-19. *J Med Virol.* 2021;93(4):2234-42. Epub 2020/11/03. doi:
746 10.1002/jmv.26648. PubMed PMID: 33135788.
- 747 105. NBS. Home - Regional - Quarterly by Province.
748 <https://data.stats.gov.cn/english/easyquery.htm?cn=E0102>: National Bureau of Statistics, China
749 2019.
- 750 106. Gan N. Beyond India, a growing number of Asian countries are being ravaged by fresh
751 coronavirus waves. *CNN.* 2021 May 8 2021.
- 752 107. Kothari A, Pfuhl G, Schieferdecker D, Harris CT, Tidwell C, Fitzpatrick KM, et al. The
753 Barrier to Vaccination Is Not Vaccine Hesitancy: Patterns of COVID-19 Vaccine Acceptance over
754 the Course of the Pandemic in 23 Countries. *medRxiv.* 2021:2021.04.23.21253857. doi:
755 10.1101/2021.04.23.21253857.

756 108. Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and
757 effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases,
758 hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an
759 observational study using national surveillance data. *The Lancet*. doi: 10.1016/S0140-
760 6736(21)00947-8.

761 **Supporting information**

762 **S1 Table. Search Strategy for MEDLINE**

763 **S2 Table. Characteristics of included studies (N=81)**

764 **S3 Table. Quality assessment of case reports and case series (N=81)**

765 **S1 Fig. Global map of distribution of the studies included (N=81) in the review**

766 **S1 Appendix. PRISMA checklist**

Identification

Screening

Eligibility

Included





